On Friday, ARS Pharmaceuticals Inc (NASDAQ: SPRY) opened at On Friday, higher 7.81% from the last session, before settling in for the closing price of $13.44. Price fluctuations for SPRY have ranged from $7.55 to $18.51 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -1939.16% at the time writing. With a float of $54.77 million, this company’s outstanding shares have now reached $98.13 million.
In an organization with 160 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 90.74%, operating margin of -27.87%, and the pretax margin is -15.82%.
ARS Pharmaceuticals Inc (SPRY) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of ARS Pharmaceuticals Inc is 44.24%, while institutional ownership is 53.75%. The most recent insider transaction that took place on May 20 ’25, was worth 1,451,513. In this transaction Chief Legal Officer of this company sold 102,969 shares at a rate of $14.10, taking the stock ownership to the 89,613 shares. Before that another transaction happened on May 20 ’25, when Company’s Director sold 120,000 for $14.25, making the entire transaction worth $1,710,024. This insider now owns 0 shares in total.
ARS Pharmaceuticals Inc (SPRY) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -1939.16% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
Check out the current performance indicators for ARS Pharmaceuticals Inc (SPRY). In the past quarter, the stock posted a quick ratio of 10.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.16, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -0.71 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
Let’s dig in a bit further. During the last 5-days, its volume was 1.1 million. That was inferior than the volume of 1.55 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 21.25%. Additionally, its Average True Range was 0.84.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 81.64%, which indicates a significant increase from 54.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.03% in the past 14 days, which was lower than the 69.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.86, while its 200-day Moving Average is $13.29. However, in the short run, ARS Pharmaceuticals Inc’s stock first resistance to watch stands at $14.84. Second resistance stands at $15.19. The third major resistance level sits at $15.84. If the price goes on to break the first support level at $13.84, it is likely to go to the next support level at $13.19. The third support level lies at $12.84 if the price breaches the second support level.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
There are currently 98,214K shares outstanding in the company with a market cap of 1.42 billion. Presently, the company’s annual sales total 89,150 K according to its annual income of 8,000 K. Last quarter, the company’s sales amounted to 7,970 K and its income totaled -33,940 K.
